natgillin/translations-raw huggingface dataset:
Use of tricyclic indazole compound of general formula (I): in which Y, W, X1, X2, X3, X4, X5, L1, L2, R1, R2, m and n have the meanings defined in any one of preceding claims 1 to 8, or of a salt thereof with a pharmaceutically acceptable organic or inorganic acid, for the preparation of a medicament for the treatment of a pathological state selected from the group consisting of disorders of the central nervous system, such as sleep disorders, schizophrenia, and anxiety, disorders of the smooth muscles both of the gastrointestinal system, such as irritable bowel syndrome (IBS), chronic constipation, diarrhoea, and functional dyspepsia, and of the cardiovascular system, such as hypertension, myocardial ischemia, cerebral ischemia, migraine, thrombosis, and platelet aggregation, and ocular pathologies, such as glaucoma. 
Uporaba tricikličkog spoja indazola formule (I): u kojoj Y, W, Xi, X», X3, Xay Xs, Lo Lo R4 R2, min imaju značenja definirana u bilo kojem od prethodnih zahtjeva 1 do 8, ili njegove soli s farmaceutski prihvatljivom organskom ili anorganskom kiselinom, naznačena time, da je za pripravu lijeka za liječenje patološkog stanja odabranog iz skupine koju čine poremećaji centralnog nervnog sustava, kao što su poremećaji spavanja, shizofrenia, 1 anksioznost, poremećaji glatkih mišića gastrointestinalnog sustava, kao što su sindrom nadraženih crijeva (IBS), kronična konstipacija, proljev, i funkcionalna dispepsija, 1 poremećaji glatkih mišića kardiovaskularnog sustava, kao što je hipertenzija, miokardijska ishemija, cerebralna ishemija, migrena, tromboza, i agregacija pločastih stanica, te očne patologije, kao što je glaukom.
A head according to one of claims 1 to 3, characterized in that it comprises a hinge interposed between said second pressing roller and said support frame and having a hinge axis orthogonal to said transversal direction and to the rotation axis of said first roller; motorized means being provided for rotating said second roller in opposite directions about said hinge axis. 
Glava u skladu s jednim od patentnih zahtjeva 1 do 3, naznačena time, da ima zglob koji je umetnut između drugog valjka za prešanje i navedenog nosivog okvira, a zglobna os je pod pravim kutom u odnosu na navedeni poprečni smjer 1 os rotacije navedenog prvog valjka; pri čemu su predviđena motorizirana sredstva za rotaciju navedenog drugog valjka u suprotnim smjerovima oko navedene zglobne osi.
Ar4 phenyl unsubstituted or substituted with one, two, or three R2 groups; 
Ar" fenil nesupstituiran ili supstituiran sa jednom, dvije ili tri R* skupine;
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
This mixture was treated successively with anhydrous sodium phenylsulfinate (99.6 g 0.608 mol), and bis-(copper (I) triflate) benzene complex (170 g, 0.338 mol). 
Ovu smjesu obrađuje se uzastopno bezvodnim natrijevim fenilsulfinatom (99,6 g 0,608 mol) i kompleksom bis(bakreni(I) triflat)-benzen (170 g, 0,338 mol).
This limits the mobility of the addict during treatment and often produces a perception that returning to a productive life will be difficult due to scheduling supervised dosing. 
To ograničava mobilnost ovisnika za vrijeme liječenja te često stvara predodžbu da će povratak produktivnom životu biti težak zbog rasporeda nadgledanog davanja.
Viscoelastic gels and hydrogels made of autocrosslinked hyaluronic acid (ACP) mixed with hyaluronic acid crosslinked with BDDE (HBC) in a weight ratio from 5:95 to 50:50, for use in applications in ophthalmic surgery as antifibrotic gels. 
PATENTNI ZAHTJEVI Viskoelastični gelovi 1 hidrogelovi naznačeni time da su pripravljeni od samoumrežene hialuronske kiseline (ACP, engl. autocrosslinked hyaluronic acid) s 1,4-butandiol-diglicil-eterom BDDE (HBC) masenih omjera od 5:95 do 50:50, za upotrebu pri operacijama oka kao antifibrotični gelovi.
In addition, these compounds are indicated to be useful for the regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia and anorexia nervosa. 
Uz to, za ove spojeve je naznačeno da su korisni za regulaciju teka i unosa hrane kod pacijenata koji boluju od poremećaja poput pretilosti, anoreksije bulimije i anoreksije nervoze.
heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, and pyrazyl, each optionally substituted with one or two substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, and polyhalo-C1-3alkyloxy; or an addition salt or a solvate thereof. 
heteroaril je odabran iz skupine koju čine piridil, pirimidil, i pirazil, svaki proizvoljno supstituiran s jednim ili dva supstituenta odabrana iz skupine koju čine halo, cijano, C1-3alkil, C1-3alkiloksi, i polihalo-C1-3alkiloksi; ili njegova adicijska sol ili solvat.
less than 4 percent by weight. 
AbO3 manje od 4 težinska postotka.
the antibody specifically binding IL-13 comprises a variable heavy chain comprising SEQ ID NO:1 or comprises a variable light chain comprising SEQ ID NO:2, the antibody specifically binding IL-13 comprises a variable heavy chain comprising SEQ ID NO:1 and comprises a variable light chain comprising SEQ ID NO:2. 
HR P20180320 T1 PATENTNI ZAHTJEVI Izolirano humanizirano protutijelo ili njegov fragment protutijela koji se specifično veže na IL-13, naznačeno time da protutijelo ili njegov fragment protutijela sadrži varijabilni laki lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 1 i sadrži varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 2.
The compound or pharmaceutically acceptable salt of claim 10, wherein cancer is fibrosarcoma, pancreatic cancer, renal cancer, liver cancer, melanoma, nasopharyngeal cancer, gastric cancer, ovarian cancer, leukemia, myeloma, breast cancer, prostate cancer, colorectal cancer, lung cancer, glioblastoma, uterine cancer, bladder cancer, mesothelioma, head cancer, neck cancer, and cervical cancer. The compound or pharmaceutically acceptable salt of claim 11, wherein said cancer is renal cancer. 
Spoj, ili farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 3, ili farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačeni time što je rak fibrosarkom, rak gušterače, rak bubrega, rak jetre, melanom, rak nazofarinksa, rak želuca, rak jajnika, leukemija, mijelom, rak dojke, rak prostate, kolorektalni rak, rak pluća, glioblastom, rak maternice, rak mokraćnog mjehura, mezoteliom, rak glave, rak vrata, te rak vrata maternice.
(VIII) welding said top layer (6) to cover and seal the top surface of said thermoformed layer (7), 
(VIII) zavarivanje navedenog gornjeg sloja (6) kako bi se pokrila i zatvorila gornja površina navedenog termoformiranog sloja (7),
A suitable additional waterproofing agent is a copolymer of vinyl pyrollidone and eicosene and dodecane monomers such as Ganex V 220 and Ganex V 216 Polymers, respectively, trade names of ISP Inc. of Wayne, N.J. U.S.A. Still other suitable waterproofing agents include polyethylene polymer, such as Performa V 825 available from New Phase Technologies and polyanhydride resin No. 18 available under the trade name PA-18 from Chevron. 
Prikladno dodatno sredstvo za vodootpornost je kopolimer vinil pirolidon 1 eikozen i dodekan monomera, kao što su Ganex V 220 1 Ganex V 216 polimeri, pojedinačno, trgovački nazivi ISP Inc. iz Wayne, NJ. SAD. Još neka prikladna sredstva za vodootpornost uključuju polietilen polimer, kao što je Performa V 825 dostupan od Ncw Phasc Tcchnologics i polianhidridna smola br. 18 dostupna pod trgovačkim nazivom PA-18 od Chevron.
Inhibition of these enzymes can lead to life-threatening conditions where the enzyme is not able to perform this function. 
Inhibiranje tih enzima može dovesti do po život opasnih stanja, u kojima enzim ne može vršiti ovu funkciju.
In embodiments, the methods involve enzymatically reacting, with the isoprenoid transferase, the expressed protein and at least one isosubstrate having a first functional group (FG1), thereby producing a functionalized protein. 
(b) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu eksprimirano antitijelo s najmanje jednim izosupstratom koji ima prvu funkcionalnu skupinu (FG1), čime se proizvodi funkcionalizirano antitijelo;
is selected from the group consisting of hydrogen, C1-4alkyl and —C1-4alkyl-O—C1-4alkyl; or a N-oxide, or a pharmaceutically acceptable salt thereof. 
je vodik, C1-4alkil ili -C1-4alkil-O-C1-4alkil; ili N-oksid, ili njegova farmaceutski prihvatljiva sol ili solvat.
Z is a 4-(C1-C12-alkyl)piperazine wherein the C1-C12-alkyl group comprises at least one further substituent independently selected from the group consisting of unsubstituted or substituted aryl, heteroaryl, (C3-C6)cycloalkyl and (C3-C6)heterocycloalkyl. 
Z je 4(C;-Cr-alkiDpiperazin, pri čemu C;-C;,-alkil-skupina sadrži barem jedan daljnji supstituent neovisno odabran iz skupine koju čine nesupstituirani ili supstituirani aril, heteroaril, (Ca-Cg)cikloalkil i (Ca-Cg)heterocikloalkil.
A compound according to item 1, wherein R1 is a direct-bonded or oxygen-linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1 R2 substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što R' je direktno vezani ili kisikom vezani zasićeni, djelomično zasićeni ili nezasićeni 5-, 6- ili 7-člani monociklični prsten koji sadrži 1, 2, 3 ili 4 atoma izabrana od N, 0 1 S, ali koji ne sadrži više od jednog O ili S, pri čemu su dostupni atomi ugljika u prstenu supstituirani sa 0, 1 ili 2 okso ili tiokso grupe, gdje je prsten supstituiran sa 0 ili 1 R* supstituentom, i prsten je dodatno supstituiran sa 0, 1, 2 ili 3 supstituenta nezavisno izabrana od halo, nitro, cijano, C,agalkil, OC,4alkil, OCi4haloalkil, NHC,.galkil, N(C,4alkiDC,salkil 1 Ci. ahaloalkil.
In a preferred embodiment, wherein said neoplastic disease is selected from the group consisting of lung cancer, head and neck cancer, central nervous system cancer, prostate cancer, testicular cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, biliary tract cancer, esophageal cancer, gastrointestinal stromal tumor, breast cancer, cervical cancer, ovarian cancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma, basal cell carcinoma, squamous cell carcinoma, bladder cancer, renal cancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome and myeloproliferative disease. 
Spoj, sol ili kompozicija, prema Zahtjevu 6, naznačeni time, što se spomenuta neoplastična bolest bira između slijedećih: kancer pluća, kancer glave 1 vrata, kancer središnjeg živčanog sustava, kancer prostate, kancer testisa, HR P20150778 T1 kolorektalni kancer, kancer pankreasa, kancer jetre, kancer želuca, kancer žučnog trakta, kancer jednjaka, gastrointestijalni stromalni tumor, kancer dojke, kancer cerviksa, kancer jajnika, kancer uterusa, leukemija, limfomi, multipli mijelom, melanom, karcinom bazalnih stanica, karcinom skvamoznih stanica, kancer mjehura, kancer bubrega, sarkom, mezotelioma, timom, mijelodisplastični sindrom i mijeloproliferativna bolest.
According to a first aspect of the invention there is provided a quinazoline derivative of the Formula I: wherein n is 0, 1, 2 or 3, 
Prema prvom aspektu ovog izuma, naveden je derivat kinazolina prikazan Formulom I:
According to a preferred aspect of the invention a method for the automatic and continuous construction and assembly of complex reticular cages derived from electro-welded metal nets with constant orthogonal meshes (1) and/or irregular orthogonal meshes (1 . 
Postupak prema zahtjevima 1 ili 2 naznačen time da su elektro-zavarene metalne mreže sa konstantnim pravokutnim rasporedom mreže (1) ili nepravilnim pravokutnim rasporedom mreže (1.1).
The method of item 117, wherein the first selected component consists essentially of hard plastic. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se prva odabrana komponenta sastoji u biti od tvrde plastike.
provided that R2 and R3 cannot both be hydrogen when R4 is a halogen, R7 is -OH and R8 is hydrogen; 
je vodik, pod uvjetom da R2 i R3 ne mogu oba biti vodik kada R4 je halogen.
A dispenser according to claim 1, wherein the counter driver guide (15) is along a back wall of the body (1). 
Dispenzer sukladno zahtjevu 12 koji sadrži treći prstenasti dio (1502) koji je koaksijalno raspoređen oko navedene uzdužne osi (214).
After 24 hr at 37° C., 5% CO2, the plate was put at −20° C. in order to submit the treated cells to a freeze/thaw cycle before performing the immunoassay to determine the quantity of IFN-Y present in the cell supernatant. 
Nakon 24 h na temperaturi 37*C, 5% CO,, pločica je bila ostavljena na -20*C zato da se tretirane stanice podvrgnu ciklusu smrzavanja/otapanja prije provođenja imuno-testa kako bi se odredila količina INF-y koji je prisutan u staničnom supernatantu.
introducing the nucleic acid of claim 14 into a cell capable of incorporating N-linked sugar moieties into the polypeptide; 
uvođenje molekula nukleinske kiseline prema patentnom zahtjevu 12 u stanicu sposobnu za ugrađivanje N-vezanih šećernih grupa u polipeptid;
This invention relates to a novel product comprising closures for pharmaceutical vials and plungers for hypodermic syringes, and to a process for using the same. 
Ovaj izum se odnosi na novi proizvod koji obuhvaća zatvarače za farmaceutske bočice i klipove za potkožne šprice, i na postupak za njihovu upotrebu.
Most preferably, Ra represents a group selected from halogen atoms and trihalomethoxy groups. 
- R? predstavlja grupu odabranu iz atoma vodika i atoma halogena; i/ili
Statement 40. The method of statement 36, wherein actuating the metered dose inhaler to provide respiratory delivery of the LAMA active agent comprises delivering the LAMA active agent at an initial fine particle fraction and the initial fine particle fraction delivered from the metered dose inhaler is substantially maintained, such that, throughout emptying of the canister, the fine particle fraction delivered from the metered dose inhaler is maintained within 80% of the initial fine particle fraction. 
Inhalator za odmjerene doze u skladu s patentnim zahtjevom 14, naznačen time što inhalator za odmjerene doze izdaje ko-suspenziju u početnoj frakciji finih čestica, gdje se početnu frakciju finih čestica izdanu iz inhalatora za odmjerene doze uglavnom održava, tako da se, tijekom pražnjenja spremnika, frakciju finih čestica unesena iz inhalatora za odmjerene doze održava unutar 80% od početne frakcije finih čestica, unutar 90% od početne frakcije
The term “prodrug esters” as employed herein includes esters and carbonates formed by reacting one or more hydroxyls of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates and the like. 
Termin "esteri prolijekova" kao što se ovdje upotrebljava uključuje estere i karbonate koji se formiraju reakcijom jedne ili više hidroksilnih skupina spojeva formule I sa alkil, alkoksi ili aril supstituiranim acilacijskim agensima upotrebom postupaka koji su poznati osobama iz struke za dobivanje acetata, pivalata, metilkarbonata, benzoata i slično.
In one aspect, the pharmaceutical composition is used for diagnosis, prevention or treatment of a hyperproliferative disease. 
Farmaceutski sastav u skladu s bilo kojim od patentnih zahtjeva 13-15 za uporabu u prevenciji ili liječenju hiperproliferativne bolesti, posebno raka.
In particular, a preferably protruding portion 20 of the actuation member 17 abuts at first stop 19 . 
Posebno, ponajprije stršeći dio 20 elementa za pokretanje 17 dodiruje prvi graničnik 19.
The reaction mixture is brought to room temperature and stirred for 4 hrs. 
Reakcijsku smjesu dovede se do sobne temperature, te miješa 4 sata.
at least one resin is provided; 
- najmanje jednu smolu.
The agent according to claim 10, wherein the neurodegenerative disease is Alzheimer's disease or multiple sclerosis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je neurodegenerativna bolest Alzheimerova bolest ili multipla skleroza.
A collection of human binding molecules on the surface of replicable genetic packages, such as a scFv phage library, as described above is another aspect of the invention. 
Postupak prema zahtjevu 1 ili 2, naznačen time da je kolekcija molekula za vezanje na površini replikativnih genetskih paketa Fv zbirka jednostrukog lanca.
is NH protecting group. 
P; je NH zaštitna skupina.
Among the cancer treatments envisaged there may be mentioned, without implying any limitation, the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, non-Hodgkin lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time, da se koristi za liječenje karcinoma mokraćnog mjehura, mozga, dojke i uterusa, kroničnih limfoidnih leukemija, kolorektalni rak, rak jednjaka i jetre, limfoblastične leukemije, ne-Hodgkinov limfomi, melanomi, hematoloških malignih bolesti, mijeloma, raka jajnika, karcinoma pluća ne-malih stanica, raka prostate i karcinoma pluća malih stanica.
The method of claim 7, wherein at least 60% of the pooled human IgG administered to the subject contacts the nasal epithelium located in the upper third of the nasal cavity of the subject. 
Pripravak prema zahtjevu 1, naznačen time, da se upotrebljava u skladu s patentnim zahtjevom 1, naznačen time što najmanje 60% skupljenog humanog IgG-a koji se daje subjektu kontaktira sa nazalnim epitelom subjekta.
the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule; 
Primjena spoja u skladu sa zahtjevima 2-7, naznačena time što se spoj ili farmaceutski prihvatljiva sol ili adukt, intravenozno daju u dozi o 10 mg do 200 mg.
The process of embodiment 12, wherein the infectious agent is selected from the group consisting of: human metapneumovirus; mumps virus; Rubellavirus; SARS coronavirus; M-strains of Rhinovirus; SV-40 polyomavirus; BK polyomavirus; JC polyomavirus; swine vesicular disease virus; Teschen-Talfan virus; Ctrachomatis; C.pneumoniae; C.psittaci; canine parvovirus; porcine parvoviruses; and infectious bursal disease virus. 
Postupak prema patentnom zahtjevu 1, naznačen time, da infekcijski agens jest jedan ili više od sljedećih patogena: humani metapneumovirus (HMPV); virus mumpsa; respiratorni sincicijski virus (RSV); humani coronavirusi; SARS corona virus; M sojevi Rhinovirusa; svinjski vezikularni virus (SVDV); pseći Parovirus, Teschen-Talfan virus; C. trachomatis; C. pneumoniae; C. psittaci.
The (S)-enantiomer of the invention modulates, preferably inhibits, ion flux through a voltage-gated sodium channel in a mammal, especially in a human. 
(S)-Enantiomer u skladu s patentnim zahtjevom 1, ili njegov farmaceutski prihvatljiv solvat, naznačen time što je namijenjen upotrebi u slabljenju struje iona kroz naponski natrijski kanal u stanici kod sisavca.
Moreover, preferred embodiments of the invention deliver an average of at least about 0.8 mg of wet total particulate matter per puff for at least about 6 puffs, preferably at least about 10 puffs, under FTC smoking conditions. 
Dalje, poželjne realizacije iz izuma provode u prosjeku najmanje oko 0.8 mg ukupne mokre čestične materije po dimu za najmanje oko 6 dimova, poželjno najmanje oko 10 dimova, pod FTC uvjetima za pušenje.
Mono- and diacylated derivatives of rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Pat. 
Mono- i diacilirani derivati rapamicina (esterificirani na položajima 28 i 43) pokazali su se korisnima kao antifungalna sredstva (U.S. pat.
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyuria by reducing nocturnal voids and/or by reducing nocturnal urine volume and/or by increasing an initial period of undisturbed sleep in a female patient in need thereof, the composition comprising an orodispersible dose of 25 microgram of desmopressin, wherein the dose is measured as the free base of desmopressin, wherein the dose is taken 0.8 to 3 hours prior to the patient's bedtime. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja muškog pacijenta koji ima nokturiju ili noćnu poliuriju, za smanjenje broja noćnih pražnjenja mjehura kod muškog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu dezmopresina od 25 µg, naznačen time da se doza mjeri kao slobodna baza dezmopresina, za administraciju prije počinka.
removing any protecting groups; ii) converting the compound of formula (1) into a further compound of formula (1) 
1i) konverziju spoja sa formulom (1) u drugi spoj sa formulom (1) ili) tvorbu soli iv) stvaranje predlijeka
The expanded, cellular material according to claim 1, wherein the physical blowing agent is either a hydrocarbon, fluorocarbon, argon, nitrogen, CO2, or a mixture thereof. 
Ekspandirani pjenasti materijal prema patentnom zahtjevu 1, naznačen time, da je fizikalni agens za upuhivanje ili ugljikovodik, fluorugljik, argon, dušik, CO2, ili njihova mješavina.
The use according to Claim 6, wherein the viral infection is caused by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus. 
Primjena prema patentnom zahtjevu 6, gdje je virusna infekcija uzrokovana virusom koji je odabran iz grupe koja se sastoji od denga virusa, virusa žute groznice, virusa Zapadnog Nila, virusa Japanskog encefalitisa, virusa krpeljnog meningoencefalitisa, Kunjin virusa, virusa encefalitisa Doline Murray, virusa encefalitisa St. Louis, virusa Omsk hemoragične groznice, virusa goveđe virusne dijareje, Zika virusa 1 virusa hepatitisa C. HR P20180572 T1
The dosage form according to the invention is also suitable for the administration of several active ingredients. 
Oblik davanja prema izumu prikladan je također za davanje više farmaceutskih djelatnih tvari u jednom obliku davanja.
A pharmaceutical composition containing at least one derivative according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier, diluent or excipient thereof. 
Farmaceutski sastav koji sadrži najmanje jedan derivat prema bilo kojem od zahtjeva od 1 do 9 i njegov farmaceutski prihvatljiv nosač, diluent ili ekscipijens.